Broad-spectrum SARS-CoV-2 Antiviral Drug Discovery Service

The outbreak and rapid spread of the novel coronavirus (SARS-CoV-2) in China have triggered a major global health crisis. As a leading biotech-company dedicated to human health improvement, Creative Biolabs now provides a full range of broad-spectrum SARS-CoV-2 antiviral drug discovery services for our worldwide customers.

Overview of the SARS-CoV-2 Infection

As the number of infected patients increases continuously, a novel coronavirus, named as SARS-CoV-2, has been identified in Wuhan, China at the end of 2019. Lately, this SARS-CoV-2 has drawn great concerns since it is a highly pathogenic coronavirus affecting humans after severe acute respiratory syndrome (SARS)-CoV. In nearly a month, over 30,000 people all over the world have been diagnosed with the SARS-CoV-2.

At present, SARS-CoV-2 is the 7th known coronavirus that can infect humans after SARS-CoV and Middle East respiratory syndrome (MERS)-CoV, etc. This SARS-CoV-2 is a single positive-stranded RNA virus classified as the sarbecovirus subgenus, Orthocoronavirinae subfamily, Coronaviridae family. The identification and characterization indicated that the highly infectious SARS-CoV-2 is closely related to SARS-CoV, which shares 89% nucleotide similarity. Differently, the SARS-CoV-2 has relatively higher pathogenicity but lower mortality compared with SARS-CoV. For SARS-CoV-2 infection therapy, isolation treatment and symptomatic treatment are the main methods currently, effective antiviral drugs and vaccines are under urgent development or evaluation.

Discovery of Broad-spectrum Antiviral Drug Against SARS-CoV-2

The broad-spectrum antiviral drug is a kind of agents used to prevent and treat virus infection. By inhibiting virus replication/reproduction in infected cells or improving cellular defense system, these broad-spectrum antiviral drugs are effective in the clinical treatment of viral infection, as well as for SARS-CoV-2 infection. Mechanisms drugs with broad-spectrum SARS-CoV-2 antiviral activities mainly involve:

• Inhibiting or killing the virus directly;
• Interference with virus attachment/membrane fusion;
• Preventing the virus from penetrating into cells;
• Inhibiting the biosynthesis of the virus;
• Inhibiting the assembly and release of the virus;
• Enhancing the antiviral ability of the host.

Fig.1 Schematic diagram of targets for broad-spectrum antiviral agents. (Zhu, 2015)

In these mechanisms of antiviral infection, the enhancement of host cellular defense is of great significance, which is the first barrier against virus infection. One of the most important factors of the first lines for the host’s antiviral defense is cytokine when the virus invades into the cells. Hence, interferons (IFNs), especially IFN-alpha and IFN-beta produced by infected cells, not only show antiviral activities but also induce various kinds of biological/immunological activities, exerting an antiviral or anti-SARS-CoV-2 role in several aspects.

Features of Our Services

• Comprehensive and advanced technology platforms
• Combination in silicon modeling analysis and experimental assays
• Highly experienced scientists and staff specialized in viral immunity
• Abundant experience in antiviral drug discovery, especially in SARS-CoV and MERS-CoV antiviral agents discovery

As a biotechnology company keeping pace with times, Creative Biolabs is highly concerned about the SARS-CoV-2 infection. Equipped with seasoned scientists and powerful technology platforms, we focus our core strength to provide various broad-spectrum antiviral drug discovery services. For anything you need, please contact us immediately.

Reference

1. Zhu, J.D.; et al. Broad-spectrum antiviral agents. Frontier in Microbiology. 2015, 6: 517.

For Research Use Only. We do not provide direct services or products for patients.